Skip to main content
Equibles

CRDL · Cardiol Therapeutics Inc. · Investor Relations

Track CRDL — free

Use CRDL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRDL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.14 +0.04 (+3.67%)
Rebalance outlook locked
Market Cap
$133.66M
Shares
121.51M
Volume · Oct 20 635.67K Avg daily vol (3M) 1.41M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-10-11 Cardiol Therapeutics Phase III MAVERIC Trial. Why Fewer Recurrences Led to More Patients Event
2026-10-09 The Deep Dive: Fewer Episodes of Recurrence, So Why Expand This Heart Drug Trial? | Interview with David Elsley Event
2026-10-08 Ellis Martin Report: Cardiol Therapeutics CEO David Elsley: Phase III MAVERIC - What Comes Next $CRDL Event
2026-09-14 Cardiol Therapeutics Fireside Chat at H.C. Wainwright's 28th Annual Global Investment Conference Conference
2026-08-11 Cardiol Therapeutics Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference Conference
2026-07-16 Cardiol Therapeutics Fireside Chat at B. Riley Securities Mind, Muscle, & Vision Summit Event
2026-07-16 B. Riley Securities Mind, Muscle & Vision Summit Event
2026-06-30 Canaccord Genuity's KOL Event Featuring Paul Cremer, M.D, the MAVERIC Phase III trial Principal Investigator and MAVERIC Program Steering Committee Member Event
2026-06-24 2026 Annual General Meeting of Shareholders Shareholder meeting
2026-05-19 Cardiol Therapeutics (CRDL) Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ Conference
2026-05-19 Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease Event
2026-04-28 Ellis Martin: Cardiol Therapeutics (CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment Event
2026-04-16 The Deep Dive Interview: Conversation with David Elsley, President and CEO of Cardiol Therapeutics (CRDL) Event
2026-04-14 Barchart Interview: Cardiol Therapeutics: The Heart Drug Story Retail Investors Aren't Talking About...Yet! Event
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2025-12-11 Discussion with David Elsley, President & CEO on the SmithWeekly Podcast Event
2025-12-01 Cardiol Therapeutics Presentation of Phase II ARCHER Trial Results Presentation
2025-10-26 Nasdaq Amplify Spotlight – Cardiol Therapeutics: Featuring President & CEO, David Elsley Event
2025-09-09 H.C. Wainwright 27th Annual Global Investment Conference Conference
2025-09-02 The KE Report Podcast: Cardiol Therapeutics – Advancing Breakthrough Therapies for Inflammatory Heart Disease Event
2025-08-12 The Deep Dive Interview: David Elsley, President & CEO of Cardiol Therapeutics Event
2025-08-12 Canaccord Genuity's 45th Annual Growth Conference Conference
2025-05-28 2025 Annual General Meeting of Shareholders Shareholder meeting
2025-04-18 The Deep Dive Interview: David Elsley, President & CEO of Cardiol Therapeutics Event
2025-03-18 37th Annual ROTH Conference Conference

Source: https://www.cardiolrx.com/investor-relations/

Key facts CIK 1702123 CUSIP 14161Y200 13F (30d) 3 filings 3 filers Visit website Investor relations